Starting Strength is the bestselling book on the most fundamental and effective approach to strength training ever written. Mark Rippetoe hosts Starting Strength Radio where he discusses topics of interest, primarily to him, but perhaps also to you.
…
continue reading
A tartalmat a Audioboom and Not So Different: a Podcast from The Center for Biosimilars biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and Not So Different: a Podcast from The Center for Biosimilars vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Player FM - Podcast alkalmazás
Lépjen offline állapotba az Player FM alkalmazással!
Lépjen offline állapotba az Player FM alkalmazással!
S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
MP3•Epizód kép
Manage episode 357041818 series 2161808
A tartalmat a Audioboom and Not So Different: a Podcast from The Center for Biosimilars biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and Not So Different: a Podcast from The Center for Biosimilars vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 epizódok
MP3•Epizód kép
Manage episode 357041818 series 2161808
A tartalmat a Audioboom and Not So Different: a Podcast from The Center for Biosimilars biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Audioboom and Not So Different: a Podcast from The Center for Biosimilars vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 epizódok
Minden epizód
×Üdvözlünk a Player FM-nél!
A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.